Market closedNon-fractional

Allogene Therapeutics/ALLO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Allogene Therapeutics

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

Ticker

ALLO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

South San Francisco, United States

Employees

233

ALLO Metrics

BasicAdvanced
$434M
Market cap
-
P/E ratio
-$1.79
EPS
0.90
Beta
-
Dividend rate
$434M
0.9
12.797
12.512
19.272
20.774
-26.71%
-55.48%
3,902.439
0.77
0.77
-1.491
-30.40%
-28.43%
-86.86%
-0.38%

What the Analysts think about ALLO

Analyst Ratings

Majority rating from 18 analysts.
Buy

ALLO Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$65M
-80.13%
Profit margin
0.00%
NaN%

ALLO Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 7.17%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.53
-$0.37
-$0.51
-$0.38
-
Expected
-$0.59
-$0.52
-$0.45
-$0.41
-$0.35
Surprise
-10.01%
-28.78%
13.55%
-7.17%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Allogene Therapeutics stock?

Allogene Therapeutics (ALLO) has a market cap of $434M as of July 06, 2024.

What is the P/E ratio for Allogene Therapeutics stock?

The price to earnings (P/E) ratio for Allogene Therapeutics (ALLO) stock is 0 as of July 06, 2024.

Does Allogene Therapeutics stock pay dividends?

No, Allogene Therapeutics (ALLO) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Allogene Therapeutics dividend payment date?

Allogene Therapeutics (ALLO) stock does not pay dividends to its shareholders.

What is the beta indicator for Allogene Therapeutics?

Allogene Therapeutics (ALLO) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Allogene Therapeutics stock

Buy or sell Allogene Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing